About Evofem Biosciences
Evofem Biosciences is a company based in San Diego (United States) founded in 2009 was acquired by Aditx Therapeutics in December 2023. It operates as a Direct-to-Consumer (D2C). Evofem Biosciences has raised $100 million across 15 funding rounds from investors including Aditx Therapeutics, Woodford Investment Management and Adjuvant Capital. The company has 32 employees as of December 31, 2024. Evofem Biosciences offers products and services including Phexxi and Solosec. Evofem Biosciences operates in a competitive market with competitors including BioNTech, Insmed, Affinivax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter San Diego, United States
- Employees 32 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evofem Biosciences, Inc.
-
Annual Revenue
$19.36 M (USD)6.28as on Dec 31, 2024
-
Net Profit
-$8.86 M (USD)-116.72as on Dec 31, 2024
-
EBITDA
-$5.42 M (USD)66.26as on Dec 31, 2024
-
Total Equity Funding
$100 M (USD)
in 15 rounds
-
Latest Funding Round
$925 K (USD), Post-IPO
Jun 26, 2025
-
Investors
Aditx Therapeutics
& 4 more
-
Employee Count
32
as on Dec 31, 2024
-
Acquired by
Aditx Therapeutics
(Dec 12, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evofem Biosciences
Evofem Biosciences is a publicly listed company on the OTC with ticker symbol EVFM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evofem Biosciences
Evofem Biosciences offers a comprehensive portfolio of products and services, including Phexxi and Solosec.
Hormone-free contraceptive gel used on-demand by women.
Product focused on women's reproductive health solutions.
People of Evofem Biosciences
Unlock access to complete
Funding Insights of Evofem Biosciences
Evofem Biosciences has successfully raised a total of $100M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $925 thousand completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evofem Biosciences
Evofem Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Aditx Therapeutics, Woodford Investment Management and Adjuvant Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is deployed for global health technology innovations.
|
Locked | Locked | Locked | |
|
Biopharmaceutical company undergoing dissolution and asset distribution processes.
|
Locked | Locked | Locked | |
|
Diversified asset management services are offered globally by Invesco.
|
Locked | Locked | Locked |
Investor details for Evofem Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evofem Biosciences
Investment portfolio details for Evofem Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evofem Biosciences
Detailed financials for Evofem Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evofem Biosciences Comparisons
Peer comparison for Evofem Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evofem Biosciences
Evofem Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioNTech, Insmed, Affinivax, Eligo Bioscience and Aridis Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Provider of human monoclonal antibodies against infectious diseases
|
|
| Locked | Locked | Locked |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
Detailed competitors of Evofem Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evofem Biosciences
Complete news archive for Evofem Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evofem Biosciences
Evofem Biosciences was founded in 2009.
Evofem Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Saundra Pelletier is the current CEO of Evofem Biosciences.
Evofem Biosciences is a funded company, having raised a total of $100M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Evofem Biosciences is 32.
Annual revenue of Evofem Biosciences is $19.36M as on Dec 31, 2024.
Evofem Biosciences, Inc. is engaged in developing and commercializing innovative products for womens sexual and reproductive health. The company is recognized for its hormone-free contraceptive gel, Phexxi, which is FDA-approved and used on-demand by women. Operations are centered in the healthcare sector, specifically targeting unmet needs in contraception with localized, non-hormonal solutions. Products are designed to empower women by offering control and flexibility in reproductive choices. Market opportunities are pursued in the multi-billion dollar womens health industry, with ongoing efforts to expand internationally through partnerships.
Evofem Biosciences's top competitors include BioNTech, Aridis Pharma and Insmed.
Evofem Biosciences offers Phexxi and Solosec.
Yes, Evofem Biosciences is publicly traded on OTC under the ticker symbol EVFM.
Evofem Biosciences has 5 investors. Key investors include Aditx Therapeutics, Woodford Investment Management, Adjuvant Capital, PDL BioPharma, and Invesco.
The ticker symbol of Evofem Biosciences is EVFM on OTC.